[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"syndrome-of-inappropriate-antidiuresis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:syndrome-of-inappropriate-antidiuresis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100579246","protein-supplementation-in-hyponatremia-due-to-the-syndrome-of-inappropriate-antidiuresis-100579246",false,"NCT06821802","Protein Supplementation in Hyponatremia Due to the Syndrome of Inappropriate Antidiuresis","Effect of Protein Supplementation in Hospitalized Patients With Hyponatremia Due to the Syndrome of Inappropriate Antidiuresis - a Monocentric Randomized Open-label Pragmatic Active-controlled Trial - the TREASUREx Trial","TREASUREx","Inclusion Criteria:\n\n* Adult patients with confirmed SIAD during the hospital stay or at screening, defined by:\n* Plasma sodium concentration \\\u003C135 mmol\u002FL\n* Plasma osmolality \\\u003C300 mOsm\u002Fkg\n* Urine osmolality \\>100 mOsm\u002Fkg\n* Urine sodium concentration \\>30 mmol\u002FL\n* Clinical euvolemia (no signs of hypovolemia or hypervolemia)\n\nExclusion Criteria:\n\n* Lactose intolerance, milk protein allergy, soy allergy, nuts allergy, or hypersensitivity to components of the protein supplement.\n* Inborn metabolic disorders affecting carbohydrate, lipid, or protein metabolism.\n* Severe symptomatic hyponatremia requiring 3% NaCl or intensive care.\n* New (within the last five days) treatment with SGLT2 inhibitors, vaptans or oral urea\n* Uncontrolled severe hypothyroidism (untreated)\n* Uncontrolled adrenal insufficiency (morning cortisol \\\u003C150nmol\u002Fl)\n* eGFR \\\u003C45 mL\u002Fmin\u002F1.73 m² (KDIGO G3b-5) or end-stage renal disease (dialysis)\n* Severe hepatic impairment or advanced symptomatic liver disease defined as past or current hepatic encephalopathy, liver cirrhosis Child C, or decompensated (bleeding, jaundice, hepatorenal syndrome)\n* Pregnancy, breastfeeding, or plans to become pregnant during the study.\n* End-of-life care\n* Lack of capacity or other reasons preventing from giving informed consent or following study procedures (e.g., due to language problems, psychological disorders, dementia, etc.)\n* Treatment with thiazid diuretic (must be stopped at least 48 hours before inclusion)\n\nPost-randomization Exclusion Criteria:\n\n* Type 1 diabetes or uncontrolled type 2 diabetes (HbA1c \\>8.0%)","ALL","18 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this study is to assess the impact of protein supplementation on hyponatremia caused by the syndrome of inappropriate antidiuresis during hospitalization.",[27,28],"Hyponatremia","Syndrome of Inappropriate Antidiuresis",[30,31,32,33],"dysregulated arginine vasopressin (AVP) secretion","increased renal AVP sensitivity","protein supplementation","fluid restriction","RECRUITING","2025-07-07",{"date":37,"type":38},"2025-07-10","ACTUAL",{"date":40,"type":38},"2025-04-14",{"date":42,"type":21},"2027-04",{"name":44,"class":45},"University Hospital, Basel, Switzerland","OTHER"]